



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: samrat@bom4.vsnl.net.in

August 5, 2017

To,
Department of Corporate Services,
BSE Limited
P J Towers,
Dalal Street,
Mumbai - 400 001.

Ref: Scrip Code: 530125

Dear Sir/Madam,

Sub: Intimation of Postponement of Meeting of the Board of Directors for approval of Unaudited Financial Results & Closure of Trading Window for the quarter ended June 30, 2017

Pursuant to Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Financial Results are required to be submitted to the Stock Exchanges with 45 days from the end of each quarter.

However, in order to facilitate smooth transition during the first year of Ind-AS implementation, the Securities and Exchange Board of India vide its Circular No. CIR/CFD/FAC/62/2016 Dated July 5, 2016, has granted an extension of one month i.e. until September 14, 2017 for submitting the Financial Results for the quarter ended June 30, 2017 to the listed entities.

Further, in accordance with the Companies (Indian Accounting Standards) Rules, 2015, Ind-AS will be implemented by our Company for the FY 2017-18.

We would like to inform you that in accordance with the extension granted by the said SEBI Circular, the Company proposes to convene and hold the meeting of the Board of Directors for approval of Financial Results for the quarter ended June 30, 2017 on September 13, 2017 by availing of the said extension.

This intimation supersedes the intimation vide letter dated July 14, 2017 submitted to the exchange with regard to Regulation 33(3) of SEBI (LODR) Regulations, 2015 on the date of the Board Meeting.

Further, the Trading window for dealing in the securities of the Company by the Insiders, as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 that is closed from August 6, 2017 has been opened, with further closure from September 5, 2017 till September 15, 2017.

Copy of Notice convening Board Meeting on Wednesday, the 13th day of September, 2017 for considering and taking on record the Un-Audited Financial Results of the Company for the quarter ended June 30, 2017 and details of Window Closure for Trading by designated persons is enclosed herewith.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Samrat Pharmachem Limited


Rajesh Mehta
Executive Director





Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: samrat@bom4.vsnl.net.in

=====
NOTICE
=====

In order to facilitate smooth transition during the first year of Ind-AS implementation, the Securities and Exchange Board of India vide its Circular No. CIR/CFD/FAC/62/2016 Dated July 5, 2016, has granted an extension of one month i.e. until September 14, 2017 for submitting the Financial Results for the quarter ended June 30, 2017 to the listed entities.

Further, in accordance with the extension granted by the said SEBI Circular, the Company proposes to convene and hold the meeting of the Board of Directors for approval of Financial Results for the quarter ended June 30, 2017 on September 13, 2017 by availing of the said extension.

Earlier notice dated July 14, 2017 for convening Board Meeting & Closure of Trading Window stands cancelled.

The Board Meeting will now be held at 6.00 P.M. on Wednesday, the 13th day of September, 2017 at the Corporate Office of the Company at 701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058, *inter alia*, to consider and take on record the Un-Audited Financial Results of the Company for the quarter ended June 30, 2017.

Further, in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and as per the terms of "Code of Conduct for Prevention of Insider Trading" of the Company, the Trading Window of the Company shall remain closed from September 5, 2017 till September 15, 2017 (both days inclusive) for Directors and Designated Employees.

Date : 05/08/2017
Place : Mumbai

By Order of the Board of Directors
For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director

